TY  - JOUR

T1  - COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT)

JO  - VALUE HEALTH

PY  - 2009/05/01

AU  - Delea T

AU  - Sofrygin O

AU  - Tappenden P

AU  - Browning D

AU  - Amonkar MM

AU  - Karnon J

AU  - Lykopoulos K

ED  - 

VL  - 12

IS  - 3

SP  - A49

EP  - A49

Y2  - 2024/12/21

ER  -